35 results
424B4
BIXT
Bioxytran, Inc
2 Oct 23
Prospectus supplement with pricing info
11:36am
recorded $977,768 in R&D expenses. During the twelve months ended December 31, 2021, the Company recorded $2,013,762. The significant difference is due … interest attribution of $193,732 and $496,297 respectively. The significant difference is due to a significant reduction in the R&D activities
424B4
fg4y3l2s 4t
14 Aug 23
Prospectus supplement with pricing info
8:07pm